长链非编码RNA FOXD2-AS1对卵巢癌细胞增殖和迁移的影响

  目的  观察长链非编码RNA（lncRNA）FOXD2-AS1对卵巢癌细胞增殖和迁移的影响。  方法  收集2017年2月至2017年9月华中科技大学同济医学院附属武汉儿童医院（武汉市妇幼保健院）手术切除的16例卵巢癌患者的组织标本,采用荧光实时定量聚合酶链式反应（quantitative PCR,qPCR）检测组织标本、人卵巢癌细胞系及人正常卵巢上皮细胞系中的FOXD2-AS1表达水平。将HO-8910细胞分为实验组和对照组,分别转染siRNA-FOXD2-AS1和阴性对照RNA。细胞计数CCK-8法、Transwell迁移实验分别检测沉默FOXD2-AS1表达对卵巢癌HO-8910细胞增殖活性和迁移能力的影响。生物信息学方法预测FOXD2-AS1的下游靶基因,qPCR检测下游靶基因表达,Western blot法检测葡萄糖调节蛋白94（glucose regulated protein94,GRP94）和信号通路Wnt/β-catenin的蛋白表达。  结果  卵巢癌组织中的FOXD2-AS1相对表达量8.56±0.51明显高于正常癌旁组织的2.38±0.21（P < 0.01）,FOXD2-AS1在卵巢癌细胞系OC3、HO-8910、A2780、SKOV-3中表达明显增加（P < 0.05）。下调FOXD2-AS1表达明显抑制卵巢癌HO-8910细胞的增殖活性和迁移能力（均P < 0.01）。生物信息学方法显示,FOXD2-AS1靶向结合miR-150-5p后,可靶向结合GRP94基因。实验组和对照组miR-150-5p相对表达量分别为5.45±0.91和1.01±0.08（P < 0.01）,GRP94 mRNA相对表达量分别为0.32±0.05和1.02±0.11（P < 0.01）。GRP94和Wnt/β-catenin信号通路蛋白表达减少。  结论  FOXD2-AS1在卵巢癌组织和细胞系呈高表达,下调FOXD2-AS1可调控miR-150-5p表达,抑制卵巢癌HO-8910细胞的增殖和迁移,可发挥抑癌基因的功能。      

p16基因在人卵巢上皮癌细胞系中的缺失分析研究

目的：了解新型抑癌基因ｐ１６在人卵巢上皮癌细胞系中的变异情况,为认识卵巢上皮癌的形成和发展依据。方法：应用ＰＣＲ扩增、ｍＲＮＡ原位杂交和免疫细胞化学方法,对５种人卵巢上皮癌细胞系ＣＡＯＶ３、ＯＶＣＡＲ３、ＡＯ、ＨＯ－８９１０及ＨＯ－８９１０ＰＭ进行分析。结果：５种人卵巢上皮癌细胞系中只有ＣＡＯＶ３（２０％）显示ｐ１６基因纯合性缺失,ＣＡＯＶ３细胞亦无ｐ１６基因ｍＲＮＡ及蛋白表达。ＯＶＣＡＲ３、Ｈ０     

紫杉醇作用卵巢癌细胞系HO-8910后CYP1B1 mRNA及蛋白表达差异的研究

背景与目的:用紫杉醇(paclitaxel,PTX)对卵巢癌细胞系HO-8910进行体外化疗后,观察CYP1B1表达的变化,以期探讨CYP1B1基因表达与肿瘤细胞耐药的关系. 材料与方法:以不同浓度PTX(分别为30、15、7.5、3.75、1.88、0.94、0.47 μg/mi)处理H0-8910细胞.采用四甲基偶氮唑蓝(MTT)比色法检测PTX对HO-8910细胞体外生长的抑制作用,实验同时设只加培养液的对照组.以5 μg/ml PTX分别处理HO-8910细胞24 h、48 h、72 h和50#g/ml PTX处理细胞24 h后,用RT-PCR技术检测存活的卵巢癌细胞中CYP1B1 mRNA的表达水平,用Western blot检测细胞CYP1B1蛋白表达.结果:PTX能抑制HO-8910细胞生长,7种不同浓度的PTX作用72 h后,细胞的抑制率分别为89.10%、76.82%、67.39%、57.27%、46.21%、37.02%、17.56%,随着药物浓度的下降,其抑制率明显降低,各浓度组细胞抑制率间的差异具有统计学意义(P<0.05).经PTX处理后存活的HO-8910细胞中CYP1B1 mRNA及蛋白的表达量增加,高于对照组;5 μg/ml PTX处理HO-8910细胞48 h、72 h和50 μg/ml的PTX处理24 h组,CYP1B1蛋白的表达量高于5 μg/ml PTX处理24 h组(P<0.05).结论:CYP1B1在卵巢癌细胞系中呈高表达,CYP1B1基因在卵巢癌细胞系H0-8910体外PTX化疗中起抑制作用.     

小分子干扰RNA抑制TNC基因的表达并逆转卵巢癌紫杉醇耐药

目的 研究小分子干扰RNA(siRNA)介导的RNA干扰(RNAi)对卵巢癌紫杉醇耐药细胞TNC基因表达的影响,探讨TNC基因在紫杉醇耐药中的功能.方法 用脂质体转染剂LipofectamineTM2000将针对TNC基因特异性合成的siRNA转染SKOV3/TAX30细胞,分别在转染后24、48、72 h收集细胞,检测各组细胞TNC mRNA和TNC蛋白的表达水平.siRNA转染SKOV3/TAX30细胞后,采用MTT法检测细胞对紫杉醇的半数抑制浓度(IC50).Western Blot检测SKOV3/TAX30及SKOV3/TAX300两种耐药细胞Wnt信号通路中关键蛋白β-catenin及下游Cyclin D、E-cadherin蛋白的表达.结果 siRNA转染SKOV3/TAX30细胞24、48、72 h后,TNC mRNA和TNC蛋白表达水平均下降,SKOV3/TAX30细胞对紫杉醇药物的IC50下降.TNC表达升高的耐药细胞中,Wnt信号通路中关键蛋白β-catenin及下游Cyclin D蛋白表达上调,E-cadherin蛋白表达下调.结论 针对TNC基因特异性合成的siRNA可激发RNAi介导的TNC沉默,并且逆转了紫杉醇化疗耐药,TNC表达上调与紫杉醇耐药相关,TNC可能通过Wnt信号通路的激活参与了化疗耐药.     

Silencing of IQGAP1 by shRNA inhibits the invasion of ovarian carcinoma HO-8910PM cells in vitro

Background

IQGAP1 is a scaffolding protein and overexpressed in many human tumors, including ovarian cancer. However, the contribution of IQGAP1 to invasive properties of ovarian cancer cells remains unknown. Here, we investigated the effect of IQGAP1-specific short hairpin RNA (shRNA) expressing plasmids on metastatic potential of ovarian cancer HO-8910PM cells.

Methods

We used RT-PCR and Western blot analysis to characterize expression of IQGAP1 in three human ovarian cancer-derived cell lines SK-OV-3, HO-8910 and HO-8910PM. We then determined whether expression of endogenous IQGAP1 correlated with invasive and migratory ability by using an in vitro Matrigel assay and cell migration assay. We further knocked down IQGAP1 using shRNA expressing plasmids controlled by U1 promoter in HO-8910PM cells and examined the proliferation activity, invasive and migration potential of IQGAP1 shRNA transfectants using MTT assay, in vitro Matrigel-coated invasion assay and migration assay.

Results

IQGAP1 expression level seemed to be closely associated with the enhanced invasion and migration in ovarian cancer cell lines. Levels of both IQGAP1 mRNA and protein were significantly reduced in HO-8910PM cells transfected with plasmid-based IQGAP1-specific shRNAs. RNAi-mediated knockdown of IQGAP1 expression in HO-8910PM cells resulted in a significant decrease in cell invasion and migration.

Conclusion

Our findings support the hypothesis that IQGAP1 promotes tumor progression and identify IQGAP1 as a potential therapeutic strategy for ovarian cancer and some other tumors with over-expression of the IQGAP1 gene.     

Glucose-regulated protein 78 as a novel effector of BRCA1 for inhibiting stress-induced apoptosis

The tumor suppressor BRCA1 is mutated in a high percentage of familial breast and ovarian cancer, but our understanding of its mechanisms of action remains incomplete. We report here that glucose-regulated protein (GRP)-78, a critical regulator of the unfolded protein response (UPR), is a novel downstream target of BRCA1. We showed that overexpression of wild-type BRCA1 suppressed the expression of GRP78, whereas expression of mutant BRCA1 gene or targeted inhibition of endogenous BRCA1 using small-interfering RNA (siRNA) enhanced GRP78 expression. Knockdown of BRCA1 also led to induction of other components of UPR, such as GRP94 and CHOP. Consistent with a role of BRCA1 knockdown in mediating cell survival, forced expression of GRP78 stimulated cell proliferation and prevented apoptosis, including that induced by endoplasmic reticulum stress and chemotherapy, in ovarian OVCAR-3 and breast MCF-7 cancer cells. Overexpression of wild-type BRCA1 could increase the apoptosis of GRP78-overexpressing cells. Conversely, knockdown GRP78 by siRNA sensitized ovarian and breast cancer cells to apoptosis. This effect was reduced when the expression of BRCA1 was simultaneously knockdown by siRNA, indicating that BRCA1 also negatively regulates GRP78-mediated cell survival and resistance to apoptosis.     

FAP-1在卵巢癌细胞株中的表达与意义

目的 :探讨Fas相关磷酸酯酶 -1(FAP 1)在卵巢癌细胞株SKOV3、HO 8910、TC 1和 3AO中的表达与意义。方法 :采用免疫印迹法和逆转录聚合酶链式反应方法 ,检测了 4种卵巢癌细胞株中FAP 1蛋白与核酸的表达水平 ;应用四唑盐比色法和流式细胞术检测了经抗Fas激活性抗体DX2诱导凋亡后 ,FAP 1分子与 4种细胞对凋亡敏感性的关系。结果 :FAP 1蛋白与mRNA的表达结果一致 ,均在SKOV3和HO 8910细胞中有表达 ,以SKOV3表达最强 ,而在TC 1和 3AO中未见表达。当用DX2以不同时间诱导凋亡后 ,FAP 1阴性株的细胞抑制率与凋亡率均高于FAP 1阳性株 ,P<0 0 5 ,P <0 0 1;而FAP 1阳性株中 ,HO 8910的生长抑制率又高于SKOV3 ,P <0 0 5。同时 ,FAP 1阴性株对DX2的反应具有时间依赖性 ,而FAP 1阳性株却表现出对DX2的逐渐耐受性。结论 :FAP 1对细胞凋亡的敏感性具有负性调控作用 ,可能对卵巢癌的发病和耐药具有重要意义     

高低转移人卵巢癌细胞系基因表达谱差异

目的 用基因芯片技术研究高低转移人卵巢癌细胞系（HO－8910PM和HO－8910）基因表达谱差异,筛选与转移相关的基因。方法 分别抽提高低转移人卵巢癌细胞和对照正常卵巢上皮的总RNA并纯化mRNA;分别将等量的mRNA逆转录合成以图像,用软件对扫描图像进行数字化处理和分析。结果 HO－8910细胞与正常卵巢上皮比较差异3倍以上共有355个基因;HO－8910PM细胞与正常卵巢上皮比较差异3倍以上共有323个基因。HO－8910PM与母系HO－8910比较差异2倍以上共有163个基因,差异3倍以上共有21个基因。结论 两株人卵巢癌细胞与正常卵巢上皮细胞基因表达谱存在差异,提示这些基因与卵巢癌的发生和发展有关;HO－8910PM与HO－8910比较存在差异的基因可能与高转移特性相关。     

抑癌基因DOC-2对卵巢癌细胞增殖的影响

目的:探讨抑癌基因DOC2对卵巢癌细胞系HO8910在生长代谢、超微结构及细胞周期等方面的影响及其作用机制。方法:实验分3组:卵巢癌细胞系HO8910、8910P93(转染并表达DOC2基因)、8910pcDNA3.1(转染空载体pcDNA3.1),通过细胞消化计数法和3HTdR掺入法分别测定3组细胞的生长曲线及DNA合成代谢情况;利用透射电镜对细胞的超微结构进行观察比较;最后利用流式细胞仪观察卵巢癌细胞转染前后细胞周期的变化。结果:8910P93在生长增殖及DNA合成方面均明显低于HO8910和8910pcDNA3.1(P<0.05),而后两者之间无明显差异;电镜结果显示,8910P93存在内质网扩张,线粒体空泡化,溶酶体增生,部分细胞可见染色质边集等凋亡前期改变;细胞周期检测结果显示,处于G1和G2期的8910P93细胞明显增多而S期细胞明显减少。结论:抑癌基因DOC2可通过改变卵巢癌细胞的形态及细胞周期而明显抑制细胞的增殖。     

The gene expression profile of highly metastatic human ovarian cancer cell line by gene chip

In this paper, gene chip technique was used to analyze the difference of gene expression patterns in highly metastatic human ovarian tumor cell line HO-8910PM and in normal ovarian epithelial cells to explore the tumor-associated gene-cluster and its function in the process of occurrence an development of ovarian carcinoma. It will be helpful to comprehensively understand the molecular mechanism of cell transformation, to provide the molecular markers and target genes for clinical diagnosis a…     

亚毒性浓度顺铂联合紫花牡荆素体外诱导人卵巢癌细胞调亡(英文)

Objective: The aim of the study was to investigate the effect of Casticin (CAS) combination with Cisplatin (DDP) in sub-toxic concentration on apoptosis of human ovarian cancer HO-8910 cells in vitro and unravel the associated mechanisms. Methods: Human ovarian cancer HO-8910 cells were cultured in vitro. The inhibitory effect of CAS combination with DDP in sub-toxic concentration on viability of human ovarian cancer HO-8910 cells was evaluated by the MTT assay. Morphological changes of cell apoptosis were detected by Hoechst 33258 staining assay. Cell apoptosis rate was analyzed by flow cytometry. The protein expression level was analyzed by Western blot. Results: CAS in sub-toxic concentration and DDP in sub-toxic concentration could slightly inhibit Human ovarian cancer HO-8910 cells, but CAS combination with DDP in sub-toxic concentration significantly inhibited the growth of HO-8910 cells, and growth inhibition rate was increased drastically compared with the control group (P﹤0.01), and the inhibiting effect showed synergistic action. Human ovarian cancer HO-8910 cells showed the typical morphological changes of apoptosis and apoptosis rate markedly increased when they were exposed to CAS combination with DDP in sub-toxic concentration for 48 h. Western blot showed that the expression of bcl-2 protein was down-regulated and protein level of caspase-3 was activated by CAS combination with DDP in sub-toxic concentration. Conclusion: CAS combination with DDP in sub-toxic concentration could inhibit the cells growth and lead to cell apoptosis in human ovarian cancer HO-8910 cells. And the down-regulation of bcl-2 protein expression and activation of caspase-3 protein might contribute to CAS combination with DDP in sub-toxic concentration in human cancer HO-8910 cells.     

人反义VEGF基因表达载体的构建及其对卵巢癌细胞增殖的影响

目的：构建人反义VEGF基因真核表达载体,进行抗血管生成治疗卵巢癌实验。方法：RT－PCR法获得人VEGF基因,将VEGF基因反向克隆入真核表达载体pcDNA3中,酶切鉴定结果。用此真核表达载体转染人卵巢癌细胞HO－8910,G418筛选获得阳性克隆,RNA斑点杂交鉴定HO－8910细胞中VEGF表达。Western blot及间接免疫荧光法检测转染前后HO－8910 细胞中VEGF蛋白表达。检测转染前后瘤细胞的生物学性状及裸鼠体内致瘤性。结果：RT－PCR法得到VEGF基因,并获得反向构建的VEGF真核表达载体。VEGF反义RNA部分阻断了HO－8910细胞中VEGF表达,转染后单个细胞的克隆形成能力明显减弱;细胞周期中,G1期细胞增多,S期细胞减少,细胞增殖能力降低;形态学超微结构显示细胞器扩张和肿胀,核染色质边集,凝集成块,可见明显的凋亡改变。裸鼠体内致瘤性降低。结论：成功构建了反义VEGF基因真核表达载体,该载体可明显抑制卵巢癌细胞增殖,为卵巢癌的基因治疗提供了一定的实验依据。     

siRNA干扰ERCC2表达影响食管癌细胞KYSE150对紫杉醇的敏感性

目的:通过siRNA干扰沉默食管癌KYSE150细胞中切除修复鼠缺陷交叉互补基因2(excision repair cross-complementing rodent repair deficiency,complementatin group 2,ERCC2)的表达,以观察其对紫杉醇(paclitaxel, PTX)敏感性的改变,初步探讨逆转KYSE150细胞对PTX耐药性的新的可能机制.方法:体外合成靶向ERCC2的小干扰RNA(small interfering RNA,siRNA);脂质体法瞬时转染ERCC2高表达细胞株KYSE150;RT-PCR和FCM分别检测转染组细胞中ERCC2 mRNA和蛋白的表达水平;MTT法检测转染前后细胞对PTX敏感性的变化.结果:RT-PCR检测结果提示,si-ERCC2组在转染后24、48和72 h时细胞中均未测出ERCC2 mRNA 特异性条带的表达;FCM检测结果提示, si-ERCC2组中ERCC2蛋白表达量随着处理时间(24、48和72 h) 的延长而逐渐下降,表达量分别下调了31.2%、51.6%和60.0%(P<0.01); si-ERCC2组PTX的IC_(50)值为(6.32±0.87 )mg/mL,与对照组比较,IC_(50)值明显降低(P<0.01).结论:siRNA成功封闭了目的基因ERCC2在转录和翻译水平上的表达,封闭ERCC2表达能部分逆转KYSE150细胞对PTX的耐药性.     

MTA1在卵巢癌中的表达及其对卵巢癌细胞侵袭转移影响的研究

  目的  研究转移相关基因1(metastasis-associated-gene1, MTA1)表达与卵巢癌发生发展转移的关系, 研究MTA1对卵巢癌侵袭转移能力的影响, 并探讨抑制卵巢癌侵袭转移的潜在靶点。  方法  免疫组织化学法检测110例卵巢癌组织中MTA1的蛋白表达水平, 分析MTA1蛋白表达与卵巢癌分化程度、临床分期及与腹腔转移的关系。并通过脂质体介导方法, 将特异性siRNA表达载体psilenter2.0-MTA1-siRNA转染入人卵巢癌细胞系HO-8910PM, 采用RT-PCR以及Western blot检测特异性siRNA对MTA1mRNA及蛋白表达的抑制效果。应用划痕损伤实验及Transwell实验检测MTA1对卵巢癌细胞侵袭转移能力的影响。  结果  MTA1随卵巢癌组织学分化程度的升高而降低, 呈负相关, MTA1的表达随着FIGO分期期别的增加而增加, 呈正相关, MTA1的表达随卵巢癌腹腔转移而增加, 呈正相关。RT-PCR及Western blot结果显示, siRNA成功抑制卵巢癌细胞系HO-8910PM中MTA1的表达。划痕损伤实验显示转染后划痕损伤愈合明显减慢, 迁移率明显降低, Transwell体外侵袭实验结果显示, 转染后穿膜细胞百分率显著降低(P < 0.05)。  结论  MTA1表达水平的增高与卵巢癌的分化程度、临床分期及远处转移密切相关, 体外研究显示抑制MTA1在卵巢癌细胞中的表达, 使细胞生长、侵袭及转移能力均受到抑制, 提示MTA1在卵巢癌的远处侵袭转移过程中发挥重要作用, 可能成为卵巢癌基因治疗的潜在靶点。      

化学合成siRNA对卵巢癌SKOV3细胞中STAT3基因表达的抑制作用

目的:观察小干扰RNA(small interference RNA,siRNA)对卵巢癌SKOV3细胞STAT3表达的抑制作用及其诱导凋亡作用的机制。方法:将STAT3 siRNA经LipofectamineTM2000脂质体介导的方法将其转染到卵巢癌细胞株SKOV3。实验分为以下3组:空白对照组(未经转染的人卵巢癌SKOV3细胞)、阴性对照转染组(阴性干扰STAT3)及特异性转染组(干扰STAT3)。用MTT法检测siRNA转染后SKOV3细胞增殖活性;流式细胞仪检测其对细胞凋亡的影响,免疫荧光法检测STAT3蛋白水平的变化,qRT-PCR和Western blot方法分别检测STAT3 mRNA和蛋白表达水平的变化。结果:成功转染STAT3干扰片段,转染率达90%。siRNA干扰STAT3组明显抑制卵巢癌细胞增殖活性,细胞凋亡率33.7%,并且下调STAT3蛋白在SKOV3细胞中的表达。RT-PCR和Western blot结果显示:siRNA STAT3组明显抑制人卵巢癌细胞SKOV3中STAT3 mRNA和蛋白的表达,与对照组相比,差异有统计学意义(P<0.05)。结论:特异性转染组48h后能有效地抑制SK-OV3细胞内STAT3的表达、抑制细胞增殖,其抑制卵巢癌细胞的机制可能与抑制了STAT3信号通路,促进细胞凋亡有关,为卵巢癌的生物治疗提供了一定的依据。     

siRNA干扰ERCC2表达对食管癌细胞紫杉醇敏感性的影响

背景与目的：通过siRNA干扰沉默ERCC2基因,观察食管癌细胞株对紫杉醇敏感性的改变,初步探讨新的紫杉醇耐药可能机制。方法：体外合成靶向ERCC2的siRNA（si-ERCC2@;应用脂质体法瞬时转染ERCC2高表达细胞株KYSE150;应用RT-PCR和流式细胞术（FCM@分别检测转染组细胞ERCC2mRNA和蛋白的表达水平;应用MTT法检测转染前后细胞对紫杉醇敏感性的变化。结果：si-ERCC2组在转染后24、48、72h均未测出ERCC2特异性条带且ERCC2蛋白表达量分别下调了31.2%,51.6%和60.0%。si-ERCC2组紫杉醇IC50值为6.3&#177;0.9μg/mL,较对照组降低49%。结论：siRNA成功封闭了目的基因ERCC2在转录和翻译水平的表达,封闭ERCC2表达能部分逆转紫杉醇耐药现象。     

小分子干扰RNA对非小细胞肺癌MRP基因和药物敏感性的影响

目的：观察小分子干扰RNA（siRNA）对非小细胞肺癌（NSCLC）MRP基因、药物敏感性和细胞凋亡的影响，探讨体外肺癌耐药的高效和特异逆转耐药策略。方法：采用MRP siRNA转染，RT-PCR检测多药耐药相关蛋白MRP mRNA表达水平，流式细胞仪检测MRP蛋白表达，MTT法检测MRP siRNA的细胞毒作用，碘化丙啶（PI）染色检测MRP siRNA的细胞凋亡作用。结果：SW1573／2R120细胞转染MRP siRNA后，MRP mRNA表达明显降低，转染24h、48h和72h后MRP siRNA组的MRP蛋白表达阳性率较对照组明显减低，MRP siRNA与对照组相比对细胞生长抑制并无统计学差异，未见明显影响细胞增殖；MRP siRNA明显增加10μM阿霉素对SW1573／2R120细胞生长的抑制，并随作用时间的延长而增强，MRP siRNA＋ADM组细胞生长抑制作用与对照组相比有统计学差异，MRP siRNA协同阿霉素增强对化疗耐药肺癌细胞的凋亡作用。结论：MRP siRNA可以明显逆转体外NSCLC MRP基因编码MRP蛋白的多药耐药。     

肿瘤抑制基因DOC-2真核表达载体的构建及在卵巢癌细胞HO-8910中的表达鉴定

目的构建肿瘤抑制基因DOC-2的真核表达载体pCDNA3.1-p93,将其转入人卵巢癌细胞系HO-8910中,对其基因表达进行相关检测,为进一步研究DOC-2的功能奠定基础。方法利用XhoI酶切含有p93cDNA的质粒得到p93cDNA基因片段,将其连接入真核表达载体pCDNA3.1,并通过酶切鉴定。用脂质体介导法将真核表达载体pCDNA3.1-p93转染HO-8910,通过G418筛选稳定表达克隆;用免疫组化法观察人DOC-2蛋白在HO-8910中的表达。结果构建了DOC-2的真核表达载体pCDNA3.1-p93,并通过酶切鉴定。免疫细胞化学结果显示pIRES2-EGFP-p93成功转入HO-8910中。结论成功构建了真核表达载体pCDNA3.1-p93并在HO-8910中得到稳定表达,为研究DOC-2蛋白的功能奠定了基础。     

Mouse trophoblastic cells exhibit a dominant invasiveness phenotype over cancer cells

Invasion process occurs both in mammalian embryo implantation during development and malignant cancer cell metastasis. We investigated the interactions between trophoblasts and metastatic cancer cells and found the phenomenon that mouse trophoblastic cells invaded the monolayer of malignant cancer cells in vitro and appeared the general trait of invasiveness to more than 30 types of malignant cancer cell lines which were derived from different histological origins and with different invasive or metastatic potential. We further investigated the cellular and molecular changes in the process of mouse trophoblastic cells invading human ovarian cancer HO-8910 cells. The results show that the invasion of trophoblastic cells lead HO-8910 cells near mouse embryo to apoptosis, and expression of cell-cycle-related protein cyclinD1 and Ki-67 mRNA were steadily remained both in mouse blastocysts and human ovarian cancer HO-8910 cells, which in part explain the proliferation activities of these cells. Our study also shows that expression of some proteins including MMP-9, FAK and Integrinαvβ3 was changeable in trophoblastic cells and HO-8910 cells in the process of blastocyst invasion, which suggested temporal expression of these molecules may involved in the invasive behavior of trophoblasts cells to cancer cells.